Advertisement
Research Article

A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults

  • Vasee S Moorthy,

    Affiliations: Medical Research Council Laboratories, Banjul, Gambia, Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom

    X
  • Egeruan B Imoukhuede,

    Affiliation: Medical Research Council Laboratories, Banjul, Gambia

    X
  • Paul Milligan,

    Affiliation: Medical Research Council Laboratories, Banjul, Gambia

    X
  • Kalifa Bojang,

    Affiliation: Medical Research Council Laboratories, Banjul, Gambia

    X
  • Sheila Keating,

    Affiliation: Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom

    X
  • Pauline Kaye,

    Affiliation: Medical Research Council Laboratories, Banjul, Gambia

    X
  • Margaret Pinder,

    Affiliation: Medical Research Council Laboratories, Banjul, Gambia

    X
  • Sarah C Gilbert,

    Affiliation: Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

    X
  • Gijs Walraven,

    Affiliation: Medical Research Council Laboratories, Banjul, Gambia

    X
  • Brian M Greenwood,

    Affiliation: London School of Hygiene and Tropical Medicine, London, United Kingdom

    X
  • Adrian S. V Hill

    Affiliations: Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

    X
  • Published: October 26, 2004
  • DOI: 10.1371/journal.pmed.0010033

About the Authors

Vasee S Moorthy, Egeruan B Imoukhuede, Paul Milligan, Kalifa Bojang, Pauline Kaye, Margaret Pinder, Gijs Walraven
Medical Research Council Laboratories, Banjul, Gambia
Vasee S Moorthy, Sheila Keating, Adrian S. V Hill
Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom
Sarah C Gilbert, Adrian S. V Hill
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
Brian M Greenwood
London School of Hygiene and Tropical Medicine, London, United Kingdom

Corresponding Author

Email: vmoorthy@malariavaccine.org

Competing Interests

VSM, EBI, PM, KB, SK, PK, MP, SCG, GW, and BMG have declared that no competing interests exist. AVSH is a co-founder and equity holder in Oxxon Therapeutics, a company developing prime-boost therapeutic vaccines.

Author Contributions

VSM wrote the manuscript and clinical trial protocol, designed the case report form, and supervised recruitment, vaccination, laboratory work, and follow-up. EBI supervised recruitment, vaccination, and follow-up. PM analysed the data and helped plan the trial. KB helped plan the trial. SK conducted the immunology analysis. PK was the data manager. MP helped laboratory supervision and planning of the trial. SCG conducted preclinical development and some quality control of the vaccines. GW helped with recruitment and planning of the trial. BMG helped plan the trial. AVSH supervised development of the malaria vaccines and the immunology assays and helped plan and report the trial.